Acusphere completes Phase I trial of heart agent:
This article was originally published in Clinica
Executive Summary
Start-up drug delivery company Acusphere has completed Phase I clinical trials of its third-generation ultrasound agent for assessing myocardial perfusion in heart disease patients. The Cambridge, Massachusetts-based company's AI-700 agent is the first application of its porous microparticle technology, which is also being applied to drug delivery. The ultrasound agent is intended to withstand the impact of the ultrasound beam and therefore allow a longer imaging duration.